LP-211 is a selective and blood−brain barrier penetrant 5-HT 7 receptor agonist, with a K i of 0.58 nM, with high selectivity over 5-HT 1A receptor (K i , 188 nM) and D 2 receptor (K i , 142 nM). In Vitro LP-211 is a selective 5-HT 7 receptor agonist, with a K i of 0.58 nM, 324- and 245-fold selectivity over 5-HT 1A receptor (K i , 188 nM) and D 2 receptor (K i , 142 nM). LP-211 shows agonist properties with an EC 50 of 0.6 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo LP-211 (10 mg/kg, i.p.) rapidly reaches the systemic circulation in the mouse, with mean C max of 0.76 ± 0.32 μg/mL at 30 min . LP-211 (0.003-0.3 mg/kg, i.p.) significantly increases the micturition volume in a dose-dependent manner, and causes significant increases in voiding efficiency in spinal cord-injured (SCI) rats, and such effects can be completely reversed by SB-269970. LP-211 (0.25 and 0.50 mg/kg i.p.) improves consolidation of chamber-shape memory in rats, resulting in significant novelty-induced hyperactivity and recognition. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Oil IC50& Target:5-HT 7 Receptor 0.58 nM (Ki) 5-HT 1A Receptor 188 nM (Ki) D 2 Receptor 142 nM (Ki)